{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T23:18:04Z","timestamp":1791587884602,"version":"4.3.4"},"reference-count":266,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.addr.2026.115840","type":"journal-article","created":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T07:26:49Z","timestamp":1772782009000},"page":"115840","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Harnessing reactive oxygen species for precision medicine: ROS-Activatable PROTACs for lung Cancer"],"prefix":"10.1016","volume":"233","author":[{"given":"M.","family":"Olaz\u00e1bal-Mor\u00e1n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Bl\u00e1zquez-Barbadillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"P\u00e9rez-Izquierdo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Mu\u00f1oz-Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Garrido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2026.115840_bb0005","doi-asserted-by":"crossref","first-page":"7454","DOI":"10.1039\/D0CS00489H","article-title":"Redox mediators as charge agents for changing electrochemical reactions","volume":"49","author":"Tamirat","year":"2020","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.addr.2026.115840_bb0010","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/s41580-022-00456-z","article-title":"Defining roles of specific reactive oxygen species (ROS) in cell biology and physiology","volume":"23","author":"Sies","year":"2022","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.addr.2026.115840_bb0015","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/s41573-021-00233-1","article-title":"Targeting oxidative stress in disease: promise and limitations of antioxidant therapy","volume":"20","author":"Forman","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2026.115840_bb0020","doi-asserted-by":"crossref","DOI":"10.3390\/biom15091316","article-title":"The role of reactive oxygen species in lung Cancer development: nanomedicine as a therapeutic strategy","volume":"15","author":"Olaz\u00e1bal-Mor\u00e1n","year":"2025","journal-title":"Biomolecules"},{"key":"10.1016\/j.addr.2026.115840_bb0025","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1042\/BST20190049","article-title":"Hydrogen peroxide reactivity and specificity in thiol-based cell signalling","volume":"48","author":"Winterbourn","year":"2020","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.addr.2026.115840_bb0030","doi-asserted-by":"crossref","first-page":"7499","DOI":"10.1074\/jbc.TM117.000257","article-title":"Regulation of redox balance in cancer and T cells","volume":"293","author":"Kong","year":"2018","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2026.115840_bb0035","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ccell.2020.06.001","article-title":"Oxidative stress in Cancer","volume":"38","author":"Hayes","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.addr.2026.115840_bb0040","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1083\/jcb.201708007","article-title":"Superoxide dismutases: dual roles in controlling ROS damage and regulating ROS signaling","volume":"217","author":"Wang","year":"2018","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.addr.2026.115840_bb0045","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/9613090","article-title":"Role of catalase in oxidative stress- and age-associated degenerative diseases","volume":"2019","author":"Nandi","year":"2019","journal-title":"Oxidative Med. Cell. Longev."},{"key":"10.1016\/j.addr.2026.115840_bb0050","author":"Worldwide cancer statistics | Cancer Research UK"},{"key":"10.1016\/j.addr.2026.115840_bb0055","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1080\/13814788.2020.1846713","article-title":"Adverse events of targeted therapies reported by patients with cancer treated in primary care","volume":"26","author":"Roger","year":"2021","journal-title":"Eur. J. Gen. Pract."},{"key":"10.1016\/j.addr.2026.115840_bb0060","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21093233","article-title":"Mechanisms of multidrug resistance in Cancer chemotherapy","volume":"21","author":"Bukowski","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.addr.2026.115840_bb0065","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/nrc.2017.36","article-title":"Drugging the \u201cundruggable\u201d cancer targets","volume":"17","author":"Dang","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.addr.2026.115840_bb0070","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41568-025-00817-8","article-title":"Targeted protein degradation for cancer therapy","volume":"25","author":"Hinterndorfer","year":"2025","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.addr.2026.115840_bb0075","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1111\/bph.15014","article-title":"Proteolysis-targeting chimeras in drug development: a safety perspective","volume":"177","author":"Moreau","year":"2020","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.addr.2026.115840_bb0080","doi-asserted-by":"crossref","first-page":"12639","DOI":"10.1021\/acs.jmedchem.2c00201","article-title":"Designing soluble PROTACs: strategies and preliminary guidelines","volume":"65","author":"Garc\u00eda Jim\u00e9nez","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.addr.2026.115840_bb0085","doi-asserted-by":"crossref","first-page":"5740","DOI":"10.1039\/D2CS00200K","article-title":"Target and tissue selectivity of PROTAC degraders","volume":"51","author":"Guenette","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.addr.2026.115840_bb0090","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/j.drudis.2020.07.013","article-title":"Optimising proteolysis-targeting chimeras (PROTACs) for oral drug delivery: a drug metabolism and pharmacokinetics perspective","volume":"25","author":"Pike","year":"2020","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.addr.2026.115840_bb0095","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s40291-022-00586-2","article-title":"Smart PROTACs enable controllable protein degradation for precision Cancer therapy","volume":"26","author":"Chen","year":"2022","journal-title":"Mol. Diagn. Ther."},{"key":"10.1016\/j.addr.2026.115840_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.116062","article-title":"Development of visible-light-activatable photocaged PROTACs","volume":"265","author":"Weng","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.addr.2026.115840_bb0105","doi-asserted-by":"crossref","first-page":"34672","DOI":"10.1021\/jacs.5c09843","article-title":"Enzyme-activated sugar-coated bifunctional degraders","volume":"147","author":"Zhu","year":"2025","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.addr.2026.115840_bb0110","doi-asserted-by":"crossref","first-page":"12852","DOI":"10.1039\/D1CC05715D","article-title":"Development of hypoxia-activated PROTAC exerting a more potent effect in tumor hypoxia than in normoxia","volume":"57","author":"Cheng","year":"2021","journal-title":"Chem. Commun."},{"key":"10.1016\/j.addr.2026.115840_bb0115","doi-asserted-by":"crossref","first-page":"10072","DOI":"10.1039\/D2CC03367D","article-title":"Reactive oxygen species-responsive pre-PROTAC for tumor-specific protein degradation","volume":"58","author":"Liu","year":"2022","journal-title":"Chem. Commun."},{"key":"10.1016\/j.addr.2026.115840_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.118432","article-title":"Design of conditional and tumor-activated PROTACs for selective degradation in lung cancer","volume":"303","author":"Lin","year":"2026","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.addr.2026.115840_bb0125","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/s12943-025-02375-x","article-title":"Oxidative stress in cancer: from tumor and microenvironment remodeling to therapeutic frontiers","author":"Liang","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.addr.2026.115840_bb0130","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1101\/gad.225680.113","article-title":"The emerging role of the Nrf2-Keap1 signaling pathway in cancer","volume":"27","author":"Jaramillo","year":"2013","journal-title":"Genes Dev."},{"key":"10.1016\/j.addr.2026.115840_bb0135","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of Cancer: new dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.addr.2026.115840_bb0140","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/bs.ircmb.2021.04.001","article-title":"Reactive oxygen species and DNA damage response in cancer","volume":"364","author":"Renaudin","year":"2021","journal-title":"Int. Rev. Cell Mol. Biol."},{"key":"10.1016\/j.addr.2026.115840_bb0145","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/cdd.2014.16","article-title":"Oncogene-induced reactive oxygen species fuel hyperproliferation and DNA damage response activation","volume":"21","author":"Ogrunc","year":"2014","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.addr.2026.115840_bb0150","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1006007","article-title":"Slow replication fork velocity of homologous recombination-defective cells results from endogenous oxidative stress","volume":"12","author":"Wilhelm","year":"2016","journal-title":"PLoS Genet."},{"key":"10.1016\/j.addr.2026.115840_bb0155","first-page":"1","article-title":"Reassessing the roles of oxidative DNA base lesion 8-oxoGua and repair enzyme OGG1 in tumorigenesis","author":"Wang","year":"2024","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.addr.2026.115840_bb0160","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.cellsig.2012.01.008","article-title":"Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling","volume":"24","author":"Ray","year":"2012","journal-title":"Cell. Signal."},{"key":"10.1016\/j.addr.2026.115840_bb0165","doi-asserted-by":"crossref","first-page":"347","DOI":"10.3109\/10715762.2015.1007968","article-title":"Exploring oxidative modifications of tyrosine: an update on mechanisms of formation, advances in analysis and biological consequences","volume":"49","author":"Hou\u00e9e-L\u00e9vin","year":"2015","journal-title":"Free Radic. Res."},{"key":"10.1016\/j.addr.2026.115840_bb0170","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/s41392-023-01705-z","article-title":"Targeting the RAS\/RAF\/MAPK pathway for cancer therapy: from mechanism to clinical studies","author":"Bahar","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.addr.2026.115840_bb0175","first-page":"854","article-title":"MAPK\/ERK signaling in tumorigenesis: mechanisms of growth, invasion, and angiogenesis","volume":"24","author":"Fei","year":"2025","journal-title":"EXCLI J."},{"key":"10.1016\/j.addr.2026.115840_bb0180","doi-asserted-by":"crossref","first-page":"4058","DOI":"10.1158\/0008-5472.CAN-22-1731","article-title":"Genomic landscapes and hallmarks of mutant RAS in human cancers","volume":"82","author":"Scharpf","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2026.115840_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2019.101282","article-title":"Cysteine-based regulation of redox-sensitive Ras small GTPases","volume":"26","author":"Messina","year":"2019","journal-title":"Redox Biol."},{"key":"10.1016\/j.addr.2026.115840_bb0190","doi-asserted-by":"crossref","first-page":"8788","DOI":"10.1073\/pnas.1003428107","article-title":"Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity","volume":"107","author":"Weinberg","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.addr.2026.115840_bb0195","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1016\/j.celrep.2016.02.029","article-title":"Mutant KRas-induced mitochondrial oxidative stress in acinar cells upregulates EGFR signaling to drive formation of pancreatic precancerous lesions","volume":"14","author":"Liou","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.addr.2026.115840_bb0200","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.cell.2004.12.041","article-title":"Reactive oxygen species promote TNF\u03b1-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases","volume":"120","author":"Kamata","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.addr.2026.115840_bb0205","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1242\/jcs.02837","article-title":"Protein kinase Cdelta-mediated proteasomal degradation of MAP kinase phosphatase-1 contributes to glutamate-induced neuronal cell death","volume":"119","author":"Choi","year":"2006","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.addr.2026.115840_bb0210","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1002\/mc.23436","article-title":"Targeting mitochondrial metabolism for metastatic cancer therapy","volume":"61","author":"Passaniti","year":"2022","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.addr.2026.115840_bb0215","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-023-01827-6","article-title":"PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer","volume":"22","author":"Glaviano","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.addr.2026.115840_bb0220","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.tips.2010.12.005","article-title":"Non-genomic loss of PTEN function in cancer: not in my genes","volume":"32","author":"Leslie","year":"2011","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.addr.2026.115840_bb0225","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0014-5793(04)00112-7","article-title":"Redox regulation of PTEN and protein tyrosine phosphatases in H 2O2-mediated cell signaling","volume":"560","author":"Cho","year":"2004","journal-title":"FEBS Lett."},{"key":"10.1016\/j.addr.2026.115840_bb0230","doi-asserted-by":"crossref","first-page":"20336","DOI":"10.1074\/jbc.M111899200","article-title":"Reversible inactivation of the tumor suppressor PTEN by H2O2","volume":"277","author":"Lee","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2026.115840_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2019.101105","article-title":"Redox inhibition of protein phosphatase PP2A: potential implications in oncogenesis and its progression","volume":"27","author":"Raman","year":"2019","journal-title":"Redox Biol."},{"key":"10.1016\/j.addr.2026.115840_bb0240","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.celrep.2014.10.019","article-title":"Sestrins inhibit mTORC1 kinase activation through the GATOR complex","volume":"9","author":"Parmigiani","year":"2014","journal-title":"Cell Rep."},{"key":"10.1016\/j.addr.2026.115840_bb0245","article-title":"NF-\u03baB in biology and targeted therapy: new insights and translational implications","volume":"9","author":"Guo","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.addr.2026.115840_bb0250","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1080\/10715760701445045","article-title":"The endogenous reactive oxygen species promote NF-kappaB activation by targeting on activation of NF-kappaB-inducing kinase in oral squamous carcinoma cells","volume":"41","author":"Wang","year":"2007","journal-title":"Free Radic. Res."},{"key":"10.1016\/j.addr.2026.115840_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2020.101834","article-title":"Sustained IKK\u03b2 phosphorylation and NF-\u03baB activation by superoxide-induced peroxynitrite-mediated nitrotyrosine modification of B56\u03b33 and PP2A inactivation","volume":"41","author":"Yee","year":"2021","journal-title":"Redox Biol."},{"key":"10.1016\/j.addr.2026.115840_bb0260","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.freeradbiomed.2017.07.013","article-title":"Tyr42 phosphorylation of RhoA GTPase promotes tumorigenesis through nuclear factor (NF)-\u03baB","volume":"112","author":"Kim","year":"2017","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.addr.2026.115840_bb0265","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.freeradbiomed.2008.09.021","article-title":"Sustained oxidative stress inhibits NF-\u03baB activation partially via inactivating the proteasome","volume":"46","author":"Wu","year":"2009","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.addr.2026.115840_bb0270","doi-asserted-by":"crossref","first-page":"7130","DOI":"10.1128\/MCB.24.16.7130-7139.2004","article-title":"Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2","volume":"24","author":"Kobayashi","year":"2004","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.addr.2026.115840_bb0275","doi-asserted-by":"crossref","first-page":"18838","DOI":"10.1073\/pnas.1007387107","article-title":"Keap1 perceives stress via three sensors for the endogenous signaling molecules nitric oxide, zinc, and alkenals","volume":"107","author":"McMahon","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.addr.2026.115840_bb0280","doi-asserted-by":"crossref","first-page":"11908","DOI":"10.1073\/pnas.172398899","article-title":"Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants","volume":"99","author":"Dinkova-Kostova","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.addr.2026.115840_bb0285","first-page":"381","article-title":"Cell death, therapeutics, and the immune response in cancer, trends","volume":"9","author":"H\u00e4nggi","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.addr.2026.115840_bb0290","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/s41571-020-0341-y","article-title":"Targeting apoptosis in cancer therapy","volume":"17","author":"Carneiro","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.addr.2026.115840_bb0295","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/j.freeradbiomed.2007.06.020","article-title":"Hydrogen peroxide inhibits caspase-dependent apoptosis by inactivating procaspase-9 in an iron-dependent manner","volume":"43","author":"Barbouti","year":"2007","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.addr.2026.115840_bb0300","article-title":"RIP1 autophosphorylation is promoted by mitochondrial ROS and is essential for RIP3 recruitment into necrosome","author":"Zhang","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2026.115840_bb0305","first-page":"21","article-title":"Necroptosis and tumor progression, trends","volume":"8","author":"Yan","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.addr.2026.115840_bb0310","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/nature15514","article-title":"Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death","author":"Shi","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.addr.2026.115840_bb0315","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1093\/jmcb\/mjz020","article-title":"Mitochondrial ROS promote macrophage pyroptosis by inducing GSDMD oxidation","volume":"11","author":"Wang","year":"2019","journal-title":"J. Mol. Cell Biol."},{"key":"10.1016\/j.addr.2026.115840_bb0320","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/s41422-018-0090-y","article-title":"Tom20 senses iron-activated ROS signaling to promote melanoma cell pyroptosis","author":"Zhou","year":"2018","journal-title":"Cell Res."},{"key":"10.1016\/j.addr.2026.115840_bb0325","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abc3465","article-title":"Caspase-8-dependent gasdermin D cleavage promotes antimicrobial defense but confers susceptibility to TNF-induced lethality","volume":"6","author":"Demarco","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.addr.2026.115840_bb0330","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1038\/s41467-019-09397-2","article-title":"Gasdermin pores permeabilize mitochondria to augment caspase-3 activation during apoptosis and inflammasome activation","author":"Rogers","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2026.115840_bb0335","doi-asserted-by":"crossref","DOI":"10.1038\/s41420-022-01101-6","article-title":"Emerging mechanisms of pyroptosis and its therapeutic strategy in cancer","volume":"8","author":"Lu","year":"2022","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.addr.2026.115840_bb0340","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nature22393","article-title":"Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin","author":"Wang","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.addr.2026.115840_bb0345","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.molcel.2020.11.024","article-title":"Membrane damage during Ferroptosis is caused by oxidation of phospholipids catalyzed by the oxidoreductases POR and CYB5R1","volume":"81","author":"Yan","year":"2021","journal-title":"Mol. Cell"},{"key":"10.1016\/j.addr.2026.115840_bb0350","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.cell.2017.11.048","article-title":"Selenium utilization by GPX4 is required to prevent Hydroperoxide-induced Ferroptosis","volume":"172","author":"Ingold","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.addr.2026.115840_bb0355","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/nature24297","article-title":"Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition","volume":"551","author":"Hangauer","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.addr.2026.115840_bb0360","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nature14344","article-title":"Ferroptosis as a p53-mediated activity during tumour suppression","author":"Jiang","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.addr.2026.115840_bb0365","first-page":"91","article-title":"ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition","author":"Doll","year":"2016","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.addr.2026.115840_bb0370","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/s41556-019-0305-6","article-title":"ALOX12 is required for p53-mediated tumour suppression through a distinct ferroptosis pathway","volume":"21","author":"Chu","year":"2019","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.addr.2026.115840_bb0375","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1126\/science.abf0529","article-title":"Copper induces cell death by targeting lipoylated TCA cycle proteins","volume":"375","author":"Tsvetkov","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.addr.2026.115840_bb0380","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41568-021-00417-2","article-title":"Connecting copper and cancer: from transition metal signalling to metalloplasia","volume":"22","author":"Ge","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.addr.2026.115840_bb0385","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/s41590-017-0013-y","article-title":"Oxeiptosis, a ROS-induced caspase-independent apoptosis-like cell-death pathway","volume":"19","author":"Holze","year":"2018","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.addr.2026.115840_bb0390","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41420-023-01376-3","article-title":"Targeting oxeiptosis-mediated tumor suppression: a novel approach to treat colorectal cancers by sanguinarine","author":"Pallichankandy","year":"2023","journal-title":"Cell Death Dis."},{"issue":"2024","key":"10.1016\/j.addr.2026.115840_bb0395","first-page":"12","article-title":"Cancer statistics","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.addr.2026.115840_bb0400","author":"Lung Cancer Survival Rates | 5-Year Survival Rates for Lung Cancer | American Cancer Society"},{"key":"10.1016\/j.addr.2026.115840_bb0405","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1021\/acs.chemrestox.9b00085","article-title":"Comparison of free radical levels in the aerosol from conventional cigarettes, electronic cigarettes, and heat-not-burn tobacco products","volume":"32","author":"Shein","year":"2019","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.addr.2026.115840_bb0410","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/s42255-020-0215-8","article-title":"NADPH oxidase subunit NOXO1 is a target for emphysema treatment in COPD","volume":"2","author":"Seimetz","year":"2020","journal-title":"Nat. Metab."},{"key":"10.1016\/j.addr.2026.115840_bb0415","article-title":"NADPH oxidase isoforms in COPD patients and acute cigarette smoke-exposed mice: induction of oxidative stress and lung inflammation","volume":"11","author":"Wang","year":"2022","journal-title":"Antioxidants (Basel)"},{"key":"10.1016\/j.addr.2026.115840_bb0420","first-page":"131","article-title":"Toxicity mechanisms of cigarette smoke on mouse fetus mitochondria, Iran","volume":"14","author":"Naserzadeh","year":"2015","journal-title":"J. Pharm. Res."},{"key":"10.1016\/j.addr.2026.115840_bb0425","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.toxlet.2019.09.022","article-title":"Mitochondrial dysfunction is associated with Miro1 reduction in lung epithelial cells by cigarette smoke","volume":"317","author":"Sundar","year":"2019","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.addr.2026.115840_bb0430","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1165\/rcmb.2020-0008OC","article-title":"Mitochondrial fission mediated cigarette smoke-induced pulmonary endothelial injury","volume":"63","author":"Wang","year":"2020","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.addr.2026.115840_bb0435","doi-asserted-by":"crossref","DOI":"10.3390\/cells10081879","article-title":"Role of NRF2 in lung Cancer","volume":"10","author":"S\u00e1nchez-Ortega","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.addr.2026.115840_bb0440","article-title":"Pulmonary inhalation for disease treatment: basic research and clinical translations","volume":"25","author":"Wang","year":"2024","journal-title":"Mater. Today Bio"},{"key":"10.1016\/j.addr.2026.115840_bb0445","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24032086","article-title":"NOX dependent ROS generation and cell metabolism","volume":"24","author":"Pecchillo Cimmino","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.addr.2026.115840_bb0450","doi-asserted-by":"crossref","first-page":"10071","DOI":"10.1007\/s00210-025-03833-5","article-title":"Effect of NADPH oxidase inhibitor apocynin on human lung cancer A549 cells via Bcl-2, Bax, caspase-3, and NF-\u03baB signaling pathway, Naunyn. Schmiedebergs","volume":"398","author":"Y\u0131ld\u0131r\u0131m","year":"2025","journal-title":"Arch. Pharmacol."},{"key":"10.1016\/j.addr.2026.115840_bb0455","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215783","article-title":"Fangchinoline inhibits non-small cell lung cancer metastasis by reversing epithelial-mesenchymal transition and suppressing the cytosolic ROS-related Akt-mTOR signaling pathway","volume":"543","author":"Chen","year":"2022","journal-title":"Cancer Lett."},{"key":"10.1016\/j.addr.2026.115840_bb0460","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1158\/0008-5472.CAN-19-3158","article-title":"NOX4 inhibition potentiates immunotherapy by overcoming Cancer-associated fibroblast-mediated CD8 T-cell exclusion from tumors","volume":"80","author":"Ford","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2026.115840_bb0465","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djx121","article-title":"Targeting the Myofibroblastic Cancer-associated fibroblast phenotype through inhibition of NOX4","volume":"110","author":"Hanley","year":"2018","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.addr.2026.115840_bb0470","doi-asserted-by":"crossref","first-page":"18708","DOI":"10.1021\/acsnano.2c07440","article-title":"Inhibition of NADPH oxidase-ROS signal using hyaluronic acid nanoparticles for overcoming Radioresistance in Cancer therapy","volume":"16","author":"Zhu","year":"2022","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2026.115840_bb0475","article-title":"A Cyclodiaryliodonium NOX inhibitor for the treatment of pancreatic Cancer via enzyme-Activatable targeted delivery by sulfated glycosaminoglycan derivatives","volume":"12","author":"Pang","year":"2023","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.addr.2026.115840_bb0480","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1001\/jama.2011.1437","article-title":"Vitamin E and the risk of prostate cancer: the selenium and vitamin E Cancer prevention trial (SELECT)","volume":"306","author":"Klein","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.addr.2026.115840_bb0485","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1056\/NEJM199605023341802","article-title":"Effects of a combination of beta carotene and vitamin a on lung cancer and cardiovascular disease","volume":"334","author":"Omenn","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2026.115840_bb0490","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.cell.2019.06.005","article-title":"BACH1 stabilization by antioxidants stimulates lung Cancer metastasis","volume":"178","author":"Wiel","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.addr.2026.115840_bb0495","doi-asserted-by":"crossref","DOI":"10.1172\/JCI169671","article-title":"Antioxidants stimulate BACH1-dependent tumor angiogenesis","volume":"133","author":"Wang","year":"2023","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.addr.2026.115840_bb0500","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.ccell.2017.02.018","article-title":"O2\u00b7\u2212 and H2O2-mediated disruption of fe metabolism causes the differential susceptibility of NSCLC and GBM cancer cells to pharmacological ascorbate","volume":"31","author":"Schoenfeld","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.addr.2026.115840_bb0505","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2022.102318","article-title":"Pharmacological ascorbate improves the response to platinum-based chemotherapy in advanced stage non-small cell lung cancer","volume":"53","author":"Furqan","year":"2022","journal-title":"Redox Biol."},{"key":"10.1016\/j.addr.2026.115840_bb0510","first-page":"231","article-title":"Evaluation of the effects of Thymoquinone on oxidative stress in A549 lung Cancer cell line","volume":"14","author":"Farsiabi","year":"2023","journal-title":"Middle East J. Cancer"},{"key":"10.1016\/j.addr.2026.115840_bb0515","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2021.102130","article-title":"Identification of peroxiredoxin 6 as a direct target of withangulatin a by quantitative chemical proteomics in non-small cell lung cancer","volume":"46","author":"Chen","year":"2021","journal-title":"Redox Biol."},{"key":"10.1016\/j.addr.2026.115840_bb0520","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106739","article-title":"\u03b2-Elemene enhances erlotinib sensitivity through induction of ferroptosis by upregulating lncRNA H19 in EGFR-mutant non-small cell lung cancer","volume":"191","author":"Xu","year":"2023","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.addr.2026.115840_bb0525","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/2360427","article-title":"Brusatol enhances the chemotherapy efficacy of gemcitabine in pancreatic Cancer via the Nrf2 Signalling pathway","volume":"2018","author":"Xiang","year":"2018","journal-title":"Oxidative Med. Cell. Longev."},{"key":"10.1016\/j.addr.2026.115840_bb0530","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2024.103305","article-title":"A potential therapeutic strategy based on acute oxidative stress induction for wild-type NRF2\/KEAP1 lung squamous cell carcinoma","volume":"75","author":"S\u00e1nchez-Ortega","year":"2024","journal-title":"Redox Biol."},{"key":"10.1016\/j.addr.2026.115840_bb0535","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.1038\/s41467-019-12164-y","article-title":"Distinct initiating events underpin the immune and metabolic heterogeneity of KRAS-mutant lung adenocarcinoma","author":"Best","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2026.115840_bb0540","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/s12943-025-02401-y","article-title":"Double vulnerability of active-NRF2 lung squamous cell carcinoma to NRF2 and TRIM24","author":"S\u00e1nchez-Ortega","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.addr.2026.115840_bb0545","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1038\/ng.2396","article-title":"Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer","volume":"44","author":"Peifer","year":"2012","journal-title":"Nat. Genet."},{"key":"10.1016\/j.addr.2026.115840_bb0550","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1038\/ng.2405","article-title":"Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer","volume":"44","author":"Rudin","year":"2012","journal-title":"Nat. Genet."},{"key":"10.1016\/j.addr.2026.115840_bb0555","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature14664","article-title":"Comprehensive genomic profiles of small cell lung cancer","volume":"524","author":"George","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.addr.2026.115840_bb0560","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ccell.2017.01.006","article-title":"Chemosensitive relapse in small cell lung Cancer proceeds through an EZH2-SLFN11 Axis","volume":"31","author":"Gardner","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.addr.2026.115840_bb0565","first-page":"2131","article-title":"Precision oncology comes of age: designing Best-in-class small molecules by integrating two decades of advances in chemistry","volume":"13","author":"Stuart","year":"2023","journal-title":"Target Biology, and Data Science, Cancer Discov."},{"key":"10.1016\/j.addr.2026.115840_bb0570","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.molonc.2012.02.004","article-title":"Discovery of small molecule cancer drugs: successes, challenges and opportunities","volume":"6","author":"Hoelder","year":"2012","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.addr.2026.115840_bb0575","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/s41573-021-00195-4","article-title":"Kinase drug discovery 20 years after imatinib: progress and future directions","volume":"20","author":"Cohen","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2026.115840_bb0580","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1002\/anie.200905244","article-title":"Phosphorylation-dependent kinase-substrate cross-linking","volume":"49","author":"Suwal","year":"2010","journal-title":"Angew. Chem. Int. Ed. Eng."},{"key":"10.1016\/j.addr.2026.115840_bb0585","first-page":"229","article-title":"Targeting inactive kinases: structure as a foundation for cancer drug discovery","author":"Hosfield","year":"2007","journal-title":"Cancer Drug Design and Discovery"},{"key":"10.1016\/j.addr.2026.115840_bb0590","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2026.115840_bb0595","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.1099314","article-title":"EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy","volume":"304","author":"Paez","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.addr.2026.115840_bb0600","doi-asserted-by":"crossref","first-page":"13306","DOI":"10.1073\/pnas.0405220101","article-title":"EGF receptor gene mutations are common in lung cancers from \u201cnever smokers\u201d and are associated with sensitivity of tumors to gefitinib and erlotinib","volume":"101","author":"Pao","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.addr.2026.115840_bb0605","doi-asserted-by":"crossref","first-page":"9101","DOI":"10.1074\/jbc.M114.631580","article-title":"Gefitinib-mediated reactive oxygen specie (ROS) instigates mitochondrial dysfunction and drug resistance in lung cancer cells","volume":"290","author":"Okon","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2026.115840_bb0610","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.1002\/cam4.881","article-title":"Erlotinib induces the human non-small-cell lung cancer cells apoptosis via activating ROS-dependent JNK pathways","volume":"5","author":"Shan","year":"2016","journal-title":"Cancer Med."},{"key":"10.1016\/j.addr.2026.115840_bb0615","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/onc.2015.140","article-title":"LKB1 deficiency enhances sensitivity to energetic stress induced by erlotinib treatment in non-small-cell lung cancer (NSCLC) cells","volume":"35","author":"Whang","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.addr.2026.115840_bb0620","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.freeradbiomed.2023.01.004","article-title":"Bazedoxifene-induced ROS promote mitochondrial dysfunction and enhance osimertinib sensitivity by inhibiting the p-STAT3\/SOCS3 and KEAP1\/NRF2 pathways in non-small cell lung cancer","volume":"196","author":"Meng","year":"2023","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.addr.2026.115840_bb0625","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1001\/jama.2014.3741","article-title":"Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs","volume":"311","author":"Kris","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.addr.2026.115840_bb0630","first-page":"330","article-title":"ALK-positive lung cancer: a moving target","volume":"4","author":"Schneider","year":"2023","journal-title":"Nat. Can."},{"key":"10.1016\/j.addr.2026.115840_bb0635","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/1878-0261.13746","article-title":"Combined blockade of GPX4 and activated EGFR\/HER3 bypass pathways inhibits the development of ALK-inhibitor-induced tolerant persister cells in ALK-fusion-positive lung cancer","volume":"19","author":"Furugaki","year":"2025","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.addr.2026.115840_bb0640","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2024.101081","article-title":"Concurrent inhibition of ALK and SRC kinases disrupts the ALK lung tumor cell proteome","volume":"74","author":"Diaz-Jimenez","year":"2024","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.addr.2026.115840_bb0645","doi-asserted-by":"crossref","DOI":"10.1007\/s11136-025-04088-6","article-title":"Health-related quality of life among anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) patients treated with first- and next-generation ALK tyrosine kinase inhibitors (TKIs): a systematic review and meta-analysis","volume":"34","author":"Huang","year":"2025","journal-title":"Qual. Life Res."},{"key":"10.1016\/j.addr.2026.115840_bb0650","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.125.043620","article-title":"Increased cardiovascular risk with Lorlatinib in patients with ALK-mutated lung Cancer: a real-world comparative study","volume":"14","author":"Lin","year":"2025","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.addr.2026.115840_bb0655","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1158\/2159-8290.CD-16-1123","article-title":"Targeting ALK: precision medicine takes on drug resistance","volume":"7","author":"Lin","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.addr.2026.115840_bb0660","first-page":"2421","article-title":"Pazopanib restricts small cell lung cancer proliferation via reactive oxygen species-mediated endoplasmic reticulum stress, Thorac","volume":"13","author":"Li","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.addr.2026.115840_bb0665","article-title":"Regorafenib induces NOX5-mediated endoplasmic reticulum stress and potentiates the anti-tumor activity of cisplatin in non-small cell lung cancer cells","volume":"39","author":"Sui","year":"2023","journal-title":"Neoplasia (United States)"},{"key":"10.1016\/j.addr.2026.115840_bb0670","doi-asserted-by":"crossref","DOI":"10.1038\/s41420-023-01338-9","article-title":"Regorafenib induces Bim-mediated intrinsic apoptosis by blocking AKT-mediated FOXO3a nuclear export","volume":"9","author":"Sun","year":"2023","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.addr.2026.115840_bb0675","doi-asserted-by":"crossref","first-page":"3604","DOI":"10.3390\/molecules24193604","article-title":"Ferrocene-Based Compounds with Antimalaria\/Anticancer Activity","volume":"24","author":"Peter","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.addr.2026.115840_bb0680","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112109","article-title":"Ferrocene-containing hybrids as potential anticancer agents: current developments, mechanisms of action and structure-activity relationships","volume":"190","author":"Wang","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.addr.2026.115840_bb0685","article-title":"Targeting ferroptosis in cancer stem cells: a novel strategy to improve cancer treatment","volume":"12","author":"Wang","year":"2025","journal-title":"Genes Dis."},{"key":"10.1016\/j.addr.2026.115840_bb0690","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13102291","article-title":"Ferrocifen loaded lipid Nanocapsules: a promising anticancer medication against multidrug resistant tumors","volume":"13","author":"Idlas","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.addr.2026.115840_bb0695","doi-asserted-by":"crossref","first-page":"8802","DOI":"10.1039\/C5CS00486A","article-title":"Ferrocifen type anti cancer drugs","volume":"44","author":"Jaouen","year":"2015","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.addr.2026.115840_bb0700","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112993","article-title":"PROTACs to address the challenges facing small molecule inhibitors","volume":"210","author":"Mart\u00edn-Acosta","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.addr.2026.115840_bb0705","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ccr.2009.11.022","article-title":"Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC","volume":"17","author":"Turke","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.addr.2026.115840_bb0710","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2019.116781","article-title":"Cancer stem cell (CSC) resistance drivers","volume":"234","author":"Najafi","year":"2019","journal-title":"Life Sci."},{"key":"10.1016\/j.addr.2026.115840_bb0715","doi-asserted-by":"crossref","first-page":"14","DOI":"10.38058\/ijsl.594000","article-title":"The effect of ATP-binding cassette (ABC) transporters in human cancers","volume":"1","author":"Mesci","year":"2019","journal-title":"International Journal of Science Letters"},{"key":"10.1016\/j.addr.2026.115840_bb0720","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102043","article-title":"The role of autophagy in resistance to targeted therapies","volume":"88","author":"Mele","year":"2020","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.addr.2026.115840_bb0725","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/nrd4389","article-title":"Drugging the undruggable RAS: Mission possible?","volume":"13","author":"Cox","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2026.115840_bb0730","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1186\/s12951-025-03442-7","article-title":"Nano-formulations in disease therapy: designs, advances, challenges, and future directions","author":"Shi","year":"2025","journal-title":"Journal of Nanobiotechnology"},{"key":"10.1016\/j.addr.2026.115840_bb0735","doi-asserted-by":"crossref","first-page":"625","DOI":"10.3390\/pharmaceutics16050625","article-title":"Unlocking potential and limits of kinase inhibitors: the highway to enhanced cancer targeted therapy","volume":"16","author":"Musumeci","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.addr.2026.115840_bb0740","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/s41573-024-00914-7","article-title":"The landscape of small-molecule prodrugs","volume":"23","author":"Fralish","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2026.115840_bb0745","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.ejmech.2016.10.061","article-title":"Prodrug approach: an overview of recent cases","volume":"127","author":"Abet","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.addr.2026.115840_bb0750","doi-asserted-by":"crossref","DOI":"10.1002\/cctc.202401609","article-title":"Recent advances in the development of targeted activation strategies for Organoboron prodrugs","volume":"17","author":"Liu","year":"2025","journal-title":"ChemCatChem"},{"key":"10.1016\/j.addr.2026.115840_bb0755","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112670","article-title":"Anticancer boron-containing prodrugs responsive to oxidative stress from the tumor microenvironment","volume":"207","author":"Maslah","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.addr.2026.115840_bb0760","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1021\/acsmedchemlett.8b00539","article-title":"Enhanced tumor selectivity of 5-fluorouracil using a reactive oxygen species-activated prodrug approach","volume":"10","author":"Ai","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.addr.2026.115840_bb0765","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1021\/acsmedchemlett.7b00504","article-title":"Biocompatible boron-containing prodrugs of Belinostat for the potential treatment of solid tumors","volume":"9","author":"Zheng","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.addr.2026.115840_bb0770","doi-asserted-by":"crossref","first-page":"19278","DOI":"10.1021\/ja2073824","article-title":"Hydrogen peroxide inducible DNA cross-linking agents: targeted anticancer prodrugs","volume":"133","author":"Kuang","year":"2011","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.addr.2026.115840_bb0775","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.apsb.2023.10.020","article-title":"Tumor-targeted metabolic inhibitor prodrug labelled with cyanine dyes enhances immunoprevention of lung cancer","volume":"14","author":"Li","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.addr.2026.115840_bb0780","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3390\/polym14040687","article-title":"Applications of the ROS-responsive Thioketal linker for the production of smart nanomedicines","volume":"14","author":"Rinaldi","year":"2022","journal-title":"Polymers"},{"key":"10.1016\/j.addr.2026.115840_bb0785","doi-asserted-by":"crossref","first-page":"7116","DOI":"10.1039\/C4CC09921D","article-title":"Exploring hydrogen peroxide responsive thiazolidinone-based prodrugs","volume":"51","author":"Perez","year":"2015","journal-title":"Chem. Commun."},{"key":"10.1016\/j.addr.2026.115840_bb0790","doi-asserted-by":"crossref","first-page":"355","DOI":"10.7555\/JBR.37.20230022","article-title":"A novel synthesized prodrug of gemcitabine based on oxygen-free radical sensitivity inhibited the growth of lung cancer cells","volume":"37","author":"Chai","year":"2023","journal-title":"J. Biomed. Res."},{"key":"10.1016\/j.addr.2026.115840_bb0795","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2020.101565","article-title":"A hydrogen peroxide responsive prodrug of Keap1-Nrf2 inhibitor for improving oral absorption and selective activation in inflammatory conditions","volume":"34","author":"Lu","year":"2020","journal-title":"Redox Biol."},{"key":"10.1016\/j.addr.2026.115840_bb0800","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.7150\/thno.121977","article-title":"Design of prodrugs with reactive oxygen species as activators and their application in tumor therapy","volume":"16","author":"Xing","year":"2026","journal-title":"Theranostics"},{"key":"10.1016\/j.addr.2026.115840_bb0805","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1021\/jm2014937","article-title":"Aminoferrocene-based prodrugs activated by reactive oxygen species","volume":"55","author":"Hagen","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.addr.2026.115840_bb0810","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3390\/molecules25112545","article-title":"N-Alkylaminoferrocene-based prodrugs targeting mitochondria of Cancer cells","volume":"25","author":"Reshetnikov","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.addr.2026.115840_bb0815","article-title":"Anticancer Aminoferrocene derivatives inducing production of mitochondrial reactive oxygen species","volume":"28","author":"Gizem \u00d6zkan","year":"2022","journal-title":"Chemistry"},{"key":"10.1016\/j.addr.2026.115840_bb0820","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1039\/D4QI03268C","article-title":"Synthesis and bio-evaluation of aminoferrocene-based anticancer prodrugs as potent ferroptosis inducers","volume":"12","author":"Zhang","year":"2025","journal-title":"Inorg. Chem. Front."},{"key":"10.1016\/j.addr.2026.115840_bb0825","series-title":"Synthesis of a lysosome-targeting aminoferrocene-based prodrug NCure2","author":"Dill","year":"2024"},{"key":"10.1016\/j.addr.2026.115840_bb0830","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41392-021-00572-w","article-title":"Small molecules in targeted cancer therapy: advances, challenges, and future perspectives","author":"Zhong","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.addr.2026.115840_bb0835","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.addr.2011.02.002","article-title":"Prodrugs for improving tumor targetability and efficiency","volume":"63","author":"Mahato","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2026.115840_bb0840","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/s41392-023-01589-z","article-title":"Recent advances in targeting the \u201cundruggable\u201d proteins: from drug discovery to clinical trials","author":"Xie","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.addr.2026.115840_bb0845","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.jconrel.2024.10.054","article-title":"A reactive oxygen species-triggerable theranostic prodrug system","volume":"376","author":"Liu","year":"2024","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2026.115840_bb0850","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/s41392-024-02004-x","article-title":"Targeted protein degradation: advances in drug discovery and clinical practice","author":"Zhong","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.addr.2026.115840_bb0855","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.70132","article-title":"Proteolysis-targeting chimeras in cancer therapy: targeted protein degradation for next-generation treatment","volume":"131","author":"Anaya","year":"2025","journal-title":"Cancer"},{"key":"10.1016\/j.addr.2026.115840_bb0860","doi-asserted-by":"crossref","first-page":"8554","DOI":"10.1073\/pnas.141230798","article-title":"Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation","volume":"98","author":"Sakamoto","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.addr.2026.115840_bb0865","doi-asserted-by":"crossref","first-page":"5904","DOI":"10.1016\/j.bmcl.2008.07.114","article-title":"Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomics","volume":"18","author":"Schneekloth","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.addr.2026.115840_bb0870","first-page":"1470","article-title":"Exploring the target scope of KEAP1 E3 ligase-based PROTACs, cell","volume":"29","author":"Du","year":"2022","journal-title":"Chem. Biol."},{"key":"10.1016\/j.addr.2026.115840_bb0875","doi-asserted-by":"crossref","first-page":"5141","DOI":"10.1021\/jacs.1c00990","article-title":"DCAF11 supports targeted protein degradation by electrophilic proteolysis-targeting chimeras","volume":"143","author":"Zhang","year":"2021","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.addr.2026.115840_bb0880","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1021\/acs.jmedchem.8b01413","article-title":"Iterative design and optimization of initially inactive proteolysis targeting chimeras (PROTACs) identify VZ185 as a potent, fast, and selective von Hippel-Lindau (VHL) based dual degrader probe of BRD9 and BRD7","volume":"62","author":"Zoppi","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.addr.2026.115840_bb0885","doi-asserted-by":"crossref","first-page":"5594","DOI":"10.1021\/jacs.2c00874","article-title":"Hijacking methyl reader proteins for nuclear-specific protein degradation","volume":"144","author":"Nalawansha","year":"2022","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.addr.2026.115840_bb0890","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1021\/acschembio.9b00704","article-title":"Development of small molecule chimeras that recruit AhR E3 ligase to target proteins","volume":"14","author":"Ohoka","year":"2019","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.addr.2026.115840_bb0895","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1021\/jacs.1c03980","article-title":"Discovery of a covalent FEM1B recruiter for targeted protein degradation applications","volume":"144","author":"Henning","year":"2022","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.addr.2026.115840_bb0900","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1021\/acschembio.8b01083","article-title":"Covalent ligand screening uncovers a RNF4 E3 ligase recruiter for targeted protein degradation applications","volume":"14","author":"Ward","year":"2019","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.addr.2026.115840_bb0905","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.116096","article-title":"Progress in the controllability technology of PROTAC","volume":"265","author":"He","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.addr.2026.115840_bb0910","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12943-022-01535-7","article-title":"Clinical considerations for the design of PROTACs in cancer","author":"Nieto-Jim\u00e9nez","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.addr.2026.115840_bb0915","doi-asserted-by":"crossref","first-page":"6515","DOI":"10.3390\/molecules27196515","article-title":"Discovery of E3 ligase ligands for target protein degradation","volume":"27","author":"Lee","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.addr.2026.115840_bb0920","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-021-01434-3","article-title":"Proteolysis-targeting chimeras (PROTACs) in cancer therapy","volume":"21","author":"Li","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.addr.2026.115840_bb0925","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"B\u00e9k\u00e9s","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2026.115840_bb0930","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-024-02024-9","article-title":"New-generation advanced PROTACs as potential therapeutic agents in cancer therapy","volume":"23","author":"Wang","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.addr.2026.115840_bb0935","doi-asserted-by":"crossref","first-page":"23926","DOI":"10.1021\/acsomega.5c01241","article-title":"Prodrug strategy for PROTACs: high efficiency and low toxicity","volume":"10","author":"Li","year":"2025","journal-title":"ACS Omega"},{"key":"10.1016\/j.addr.2026.115840_bb0940","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.scib.2023.04.028","article-title":"Stimuli-activatable PROTACs for precise protein degradation and cancer therapy","volume":"68","author":"Gao","year":"2023","journal-title":"Sci. Bull. (Beijing)"},{"key":"10.1016\/j.addr.2026.115840_bb0945","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.3390\/bioengineering10121368","article-title":"Recent advances in optically controlled PROTAC","volume":"10","author":"Ouyang","year":"2023","journal-title":"Bioengineering"},{"key":"10.1016\/j.addr.2026.115840_bb0950","doi-asserted-by":"crossref","first-page":"5408","DOI":"10.1021\/acs.jcim.3c00603","article-title":"Targeted protein degradation: advances, challenges, and prospects for computational methods","volume":"63","author":"Mostofian","year":"2023","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.addr.2026.115840_bb0955","doi-asserted-by":"crossref","first-page":"35723","DOI":"10.18632\/oncotarget.26267","article-title":"Targeting the invincible barrier for drug delivery in solid cancers: interstitial fluid pressure","volume":"9","author":"Libutti","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.addr.2026.115840_bb0960","first-page":"292","article-title":"Reengineering the physical microenvironment of tumors to improve drug delivery and efficacy: from mathematical modeling to bench to bedside, trends","volume":"4","author":"Stylianopoulos","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.addr.2026.115840_bb0965","doi-asserted-by":"crossref","first-page":"6413","DOI":"10.1021\/acs.molpharmaceut.5c00474","article-title":"Drug delivery Systems for Overcoming Physical Barriers in Cancer therapy","volume":"22","author":"Yi","year":"2025","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2026.115840_bb0970","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/s12276-021-00599-7","article-title":"Tailoring photosensitive ROS for advanced photodynamic therapy","volume":"53","author":"Sai","year":"2021","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.addr.2026.115840_bb0975","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1556-0864(15)31616-6","article-title":"Photodynamic therapy (PDT) for lung cancers","volume":"1","author":"Usuda","year":"2006","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.addr.2026.115840_bb0980","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1021\/acsnano.7b09112","article-title":"Enhanced immunotherapy based on photodynamic therapy for both primary and lung metastasis tumor eradication","volume":"12","author":"Song","year":"2018","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2026.115840_bb0985","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2025.115696","article-title":"Sonodynamic therapy: transforming sound into light for hard-to-treat tumours","volume":"226","author":"Cressey","year":"2025","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2026.115840_bb0990","article-title":"Advances in light-activated PROTACs and phototherapy-combined approaches for cancer treatment","volume":"302","author":"Zhang","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.addr.2026.115840_bb0995","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1002\/cmdc.202000249","article-title":"Controlling PROTACs with light","volume":"15","author":"Verma","year":"2020","journal-title":"ChemMedChem"},{"key":"10.1016\/j.addr.2026.115840_bb1000","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aay5064","article-title":"PHOTACs enable optical control of protein degradation","volume":"6","author":"Reynders","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.addr.2026.115840_bb1005","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.118432","article-title":"Design of conditional and tumor-activated PROTACs for selective degradation in lung cancer","volume":"303","author":"Lin","year":"2026","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.addr.2026.115840_bb1010","doi-asserted-by":"crossref","first-page":"10458","DOI":"10.1021\/acs.jmedchem.3c00587","article-title":"Near-infrared-Activatable PROTAC Nanocages for controllable target protein degradation and on-demand antitumor therapy","volume":"66","author":"He","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.addr.2026.115840_bb1015","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1080\/17576180.2025.2481021","article-title":"Conquering PROTAC molecular design and drugability","volume":"17","author":"Bhole","year":"2025","journal-title":"Bioanalysis"},{"key":"10.1016\/j.addr.2026.115840_bb1020","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.chempr.2022.11.007","article-title":"Photo-controllable biochemistry: exploiting the photocages in phototherapeutic window","volume":"9","author":"Xiong","year":"2023","journal-title":"Chem"},{"key":"10.1016\/j.addr.2026.115840_bb1025","doi-asserted-by":"crossref","first-page":"18370","DOI":"10.1021\/jacs.9b06422","article-title":"Light-induced protein degradation with Photocaged PROTACs","volume":"141","author":"Xue","year":"2019","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.addr.2026.115840_bb1030","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1021\/jacs.9b12718","article-title":"Optical control of small molecule-induced protein degradation","volume":"142","author":"Naro","year":"2020","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.addr.2026.115840_bb1035","article-title":"Light-induced control of protein destruction by opto-PROTAC","volume":"6","author":"Liu","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.addr.2026.115840_bb1040","article-title":"Unconventional PROTACs for targeted protein degradation in Cancer therapy","volume":"64","author":"Zhang","year":"2025","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.addr.2026.115840_bb1045","doi-asserted-by":"crossref","first-page":"3704","DOI":"10.1021\/acschemneuro.3c00390","article-title":"Photoactivated protein degrader for optical control of synaptic function","volume":"14","author":"Ko","year":"2023","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.addr.2026.115840_bb1050","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2025.118414","article-title":"Ligand-embedded photoswitching PROTAC for spatiotemporal tubulin degradation","volume":"131","author":"Zhang","year":"2025","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.addr.2026.115840_bb1055","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1039\/D4MD00972J","article-title":"Light-activatable photochemically targeting chimeras (PHOTACs) enable the optical control of targeted protein degradation of HDAC6","volume":"16","author":"Wurnig","year":"2025","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.addr.2026.115840_bb1060","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202510641","article-title":"Tandem-Activatable PROTAC prodrug for tumor biomarker-driven near-infrared Opto-proteolysis","volume":"64","author":"Lu","year":"2025","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.addr.2026.115840_bb1065","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/nrd4002","article-title":"Modulation of oxidative stress as an anticancer strategy","volume":"12","author":"Gorrini","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2026.115840_bb1070","article-title":"Redox regulation: mechanisms, biology and therapeutic targets in diseases","volume":"10","author":"Li","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.addr.2026.115840_bb1075","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1002\/ijc.27816","article-title":"Lung carcinogenesis by tobacco smoke","volume":"131","author":"Hecht","year":"2012","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.addr.2026.115840_bb1080","doi-asserted-by":"crossref","DOI":"10.3390\/cells14151207","article-title":"Reactive oxygen species: a double-edged sword in the modulation of Cancer signaling pathway dynamics","volume":"14","author":"Nigam","year":"2025","journal-title":"Cells"},{"key":"10.1016\/j.addr.2026.115840_bb1085","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jconrel.2011.01.030","article-title":"Glutathione-responsive nano-vehicles as a promising platform for targeted intracellular drug and gene delivery","volume":"152","author":"Cheng","year":"2011","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2026.115840_bb1090","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1021\/acsbiomaterials.2c00076","article-title":"GSH-responsive and hypoxia-activated multifunctional nanoparticles for Synergetically enhanced tumor therapy","volume":"8","author":"Liu","year":"2022","journal-title":"ACS Biomater. Sci. Eng."},{"key":"10.1016\/j.addr.2026.115840_bb1095","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1021\/acsnano.8b06400","article-title":"Glutathione-responsive prodrug nanoparticles for effective drug delivery and Cancer therapy","volume":"13","author":"Ling","year":"2019","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2026.115840_bb1100","doi-asserted-by":"crossref","first-page":"6902","DOI":"10.7150\/jca.49532","article-title":"Application and development of aptamer in cancer: from clinical diagnosis to cancer therapy","volume":"11","author":"Han","year":"2020","journal-title":"J. Cancer"},{"key":"10.1016\/j.addr.2026.115840_bb1105","article-title":"Small molecules in targeted cancer therapy: advances, challenges, and future perspectives","volume":"6","author":"Zhong","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.addr.2026.115840_bb1110","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2023.117526","article-title":"Glutathione-responsive PROTAC for targeted degradation of ER\u03b1 in breast cancer cells","volume":"96","author":"Zhou","year":"2023","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.addr.2026.115840_bb1115","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106793","article-title":"Selective degradation of BRD4 suppresses lung cancer cell proliferation using GSH-responsive PROTAC precursors","volume":"140","author":"Fan","year":"2023","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.addr.2026.115840_bb1120","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.ejmech.2018.03.071","article-title":"Proteolysis targeting chimeras (PROTACs) of anaplastic lymphoma kinase (ALK)","volume":"151","author":"Zhang","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.addr.2026.115840_bb1125","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/cmdc.201900497","article-title":"Antibody conjugation of a chimeric BET degrader enables in vivo activity","volume":"15","author":"Pillow","year":"2020","journal-title":"ChemMedChem"},{"key":"10.1016\/j.addr.2026.115840_bb1130","doi-asserted-by":"crossref","first-page":"23299","DOI":"10.1002\/anie.202107347","article-title":"Aptamer-PROTAC conjugates (APCs) for tumor-specific targeting in breast Cancer","volume":"60","author":"He","year":"2021","journal-title":"Angew. Chem. Int. Ed. Eng."},{"key":"10.1016\/j.addr.2026.115840_bb1135","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1021\/jacs.9b10510","article-title":"Molecularly engineering Triptolide with aptamers for high specificity and cytotoxicity for triple-negative breast Cancer","volume":"142","author":"He","year":"2020","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.addr.2026.115840_bb1140","article-title":"Drugtamer-PROTAC conjugation strategy for targeted PROTAC delivery and synergistic antitumor therapy","volume":"11","author":"He","year":"2024","journal-title":"Adv. Sci. (Weinh)."},{"key":"10.1016\/j.addr.2026.115840_bb1145","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/s41568-021-00435-0","article-title":"The role of ROS in tumour development and progression","volume":"22","author":"Cheung","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.addr.2026.115840_bb1150","doi-asserted-by":"crossref","first-page":"4323","DOI":"10.3390\/molecules25184323","article-title":"Boronic acids and their derivatives in medicinal chemistry: synthesis and biological applications","volume":"25","author":"Silva","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.addr.2026.115840_bb1155","doi-asserted-by":"crossref","DOI":"10.1002\/cbic.202100366","article-title":"Recent advances in hydrogen peroxide responsive Organoborons for biological and biomedical applications","volume":"23","author":"Saxon","year":"2022","journal-title":"ChemBioChem"},{"key":"10.1016\/j.addr.2026.115840_bb1160","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2023.108354","article-title":"BET proteins: biological functions and therapeutic interventions","volume":"243","author":"Guo","year":"2023","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.addr.2026.115840_bb1165","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/s41573-019-0030-7","article-title":"Bromodomains: a new target class for drug development","volume":"18","author":"Cochran","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2026.115840_bb1170","doi-asserted-by":"crossref","DOI":"10.1111\/febs.70191","article-title":"Overcoming BET-inhibitor JQ1 resistance in aggressive non-small cell lung cancer by inducing ferroptosis via inhibition of the BRD2-FTH1 axis","volume":"292","author":"Scicchitano","year":"2025","journal-title":"FEBS J."},{"key":"10.1016\/j.addr.2026.115840_bb1175","doi-asserted-by":"crossref","first-page":"3809","DOI":"10.31635\/ccschem.022.202101529","article-title":"Enzyme-catalyzed activation of pro-PROTAC for cell-selective protein degradation","volume":"4","author":"Liang","year":"2022","journal-title":"CCS Chem."},{"key":"10.1016\/j.addr.2026.115840_bb1180","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1021\/acs.orglett.8b01409","article-title":"An NAD(P)H:Quinone oxidoreductase 1 responsive and self-immolative prodrug of 5-fluorouracil for safe and effective cancer therapy","volume":"20","author":"Zhang","year":"2018","journal-title":"Org. Lett."},{"key":"10.1016\/j.addr.2026.115840_bb1185","doi-asserted-by":"crossref","DOI":"10.26599\/NR.2025.94908191","article-title":"Tumor-selective degradation of PARP-1 enabled by the codelivery of \u03b2-lapachone and PROTAC for non-small-cell lung cancer therapy","volume":"19","author":"Zheng","year":"2026","journal-title":"Nano Res."},{"key":"10.1016\/j.addr.2026.115840_bb1190","doi-asserted-by":"crossref","first-page":"6328","DOI":"10.1021\/acs.jmedchem.4c02658","article-title":"Targeted degradation of Bromodomain-containing protein 4 enabled by reactive oxygen species-Activatable NanoPROTACs as an efficient strategy to reverse liver fibrosis in chronic liver injury","volume":"68","author":"Bi","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.addr.2026.115840_bb1195","article-title":"Targeting hypoxia: hypoxia-activated prodrugs in Cancer therapy","volume":"11","author":"Li","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.addr.2026.115840_bb1200","doi-asserted-by":"crossref","DOI":"10.1021\/jacs.5c10240","article-title":"Indolequinone-based hypoxia-activated proteolysis targeting chimeras selectively degrade BRD4 in hypoxic Cancer cells","author":"Serafini","year":"2025","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.addr.2026.115840_bb1205","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1200\/JCO.2014.55.7504","article-title":"Randomized phase II trial of gemcitabine plus TH-302 versus gemcitabine in patients with advanced pancreatic Cancer","volume":"33","author":"Borad","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.addr.2026.115840_bb1210","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2014.157","article-title":"The bromodomain protein BRD4 regulates the KEAP1\/NRF2-dependent oxidative stress response","volume":"5","author":"Hussong","year":"2014","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.addr.2026.115840_bb1215","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abq2216","article-title":"Hypoxia deactivates epigenetic feedbacks via enzyme-derived clicking proteolysis-targeting chimeras","volume":"8","author":"Do","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.addr.2026.115840_bb1220","doi-asserted-by":"crossref","DOI":"10.1021\/acsnano.4c09800","article-title":"Advancing proteolysis targeting chimera (PROTAC) nanotechnology in protein homeostasis reprograming for disease treatment","volume":"18","author":"Wu","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2026.115840_bb1225","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3390\/pharmaceutics17081037","article-title":"Recent advances in nanomedicine: cutting-edge research on Nano-PROTAC delivery Systems for Cancer Therapy","volume":"17","author":"Wu","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.addr.2026.115840_bb1230","article-title":"Degraders on demand: engineering smart Nanocarriers for PROTAC delivery","author":"Amalraj","year":"2025","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2026.115840_bb1235","doi-asserted-by":"crossref","first-page":"7133","DOI":"10.1038\/s41467-022-34807-3","article-title":"DeepPROTACs is a deep learning-based targeted degradation predictor for PROTACs","author":"Li","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2026.115840_bb1240","article-title":"Versatile Nano-PROTAC-induced epigenetic reader degradation for efficient lung Cancer therapy","volume":"9","author":"Zhang","year":"2022","journal-title":"Adv. Sci. (Weinh)."},{"key":"10.1016\/j.addr.2026.115840_bb1245","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2025.115135","article-title":"Selective and spatiotemporal-resolved nano-PROTAC for lung cancer therapy","volume":"257","author":"Xu","year":"2026","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"10.1016\/j.addr.2026.115840_bb1250","article-title":"Engineered bioorthogonal POLY-PROTAC nanoparticles for tumour-specific protein degradation and precise cancer therapy","volume":"13","author":"Gao","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2026.115840_bb1255","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2025.101316","article-title":"The novel strategy to overcome the drug-resistant lung cancer: dual targeting delivery of PROTAC to inhibit cancer-associated fibroblasts and lung cancer cells","volume":"84","author":"Zhang","year":"2026","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.addr.2026.115840_bb1260","doi-asserted-by":"crossref","DOI":"10.1186\/s12951-024-02967-7","article-title":"Dual targeting and bioresponsive nano-PROTAC induced precise and effective lung cancer therapy","volume":"22","author":"Guan","year":"2024","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.addr.2026.115840_bb1265","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/s41392-025-02405-6","article-title":"Reprogramming of cancer metabolism via photoresponsive nano-PROTAC enhances pyroptosis-mediated immunotherapy","author":"Park","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.addr.2026.115840_bb1270","doi-asserted-by":"crossref","first-page":"6608","DOI":"10.1038\/s41467-024-50735-w","article-title":"A region-confined PROTAC nanoplatform for spatiotemporally tunable protein degradation and enhanced cancer therapy","author":"Gao","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2026.115840_bb1275","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2023.101890","article-title":"CDK4\/6 nano-PROTAC enhances mitochondria-dependent photodynamic therapy and anti-tumor immunity","volume":"50","author":"Wang","year":"2023","journal-title":"Nano Today"},{"key":"10.1016\/j.addr.2026.115840_bb1280","article-title":"A PROTAC-based Cuproptosis sensitizer in lung Cancer therapy","volume":"37","author":"Wang","year":"2025","journal-title":"Adv. Mater."},{"key":"10.1016\/j.addr.2026.115840_bb1285","doi-asserted-by":"crossref","first-page":"168827","DOI":"10.1016\/j.cej.2025.168827","article-title":"Synergistic ferroptosis-immunotherapy nanoassembly via PROTAC-mediated SLC7A11 degradation and trisulfide-driven glutathione depletion for enhanced antitumor efficacy","volume":"524","author":"Wang","year":"2025","journal-title":"Chem. Eng. J."},{"key":"10.1016\/j.addr.2026.115840_bb1290","article-title":"CDT prodrug therapy with Cascade-activated PROTAC delivery platform for mutually reinforced Ferroptosis and apoptosis-based therapy","author":"Xu","year":"2025","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.addr.2026.115840_bb1295","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/s41586-025-09000-3","article-title":"STAT5 and STAT3 balance shapes dendritic cell function and tumour immunity","volume":"643","author":"Zhou","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.addr.2026.115840_bb1300","doi-asserted-by":"crossref","first-page":"964","DOI":"10.3390\/antiox14080964","article-title":"Reactive oxygen species and the lung cancer tumor microenvironment: emerging therapeutic opportunities","volume":"14","author":"Papavassiliou","year":"2025","journal-title":"Antioxidants"},{"key":"10.1016\/j.addr.2026.115840_bb1305","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1158\/1535-7163.MCT-23-0655","article-title":"Preclinical evaluation of Bavdegalutamide (ARV-110), a novel PROteolysis TArgeting chimera androgen receptor degrader","volume":"24","author":"Snyder","year":"2025","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.addr.2026.115840_bb1310","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJMoa2505725","article-title":"Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer","volume":"393","author":"Campone","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2026.115840_bb1315","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.omtn.2023.07.027","article-title":"Targeting oncogenic KRAS in non-small cell lung cancer with EGFR aptamer-conjugated multifunctional RNA nanoparticles","volume":"33","author":"Yang","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.addr.2026.115840_bb1320","author":"Study Details | NCT06050980 | Phase I Study of HSK40118 in NSCLC Patients With EGFR Mutation"},{"key":"10.1016\/j.addr.2026.115840_bb1325","author":"Study Details | NCT06536400 | Phase I Study of HSK42360 in Solid Tumors With BRAF V600 Mutation"},{"key":"10.1016\/j.addr.2026.115840_bb1330","doi-asserted-by":"crossref","first-page":"6070","DOI":"10.1021\/acs.jmedchem.2c01909","article-title":"ARE-PROTACs enable co-degradation of an Nrf2-MafG heterodimer","volume":"66","author":"Ji","year":"2023","journal-title":"J. Med. Chem."}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X26000748?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X26000748?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T17:01:22Z","timestamp":1775581282000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X26000748"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":266,"alternative-id":["S0169409X26000748"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2026.115840","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Harnessing reactive oxygen species for precision medicine: ROS-Activatable PROTACs for lung Cancer","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2026.115840","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115840"}}